Evaluation of Crushed Posaconazole Delayed Release Tablets in Lung Transplant Recipients
Crushed posaconazole DR tablets are a viable and cost savings option, but loading doses and higher maintenance doses may be required to reach therapeutic levels. Those who received loading doses (intravenously or crushed) followed by a daily crushed dose of 400 mg were more likely to be therapeutic. Limitations of our study include that it is single-center, small in sample size, and retrospective.
Authors
- Katherine Dewey (ORCID: https://orcid.org/0000-0002-3839-6552)
- Steven R. Hays (ORCID: https://orcid.org/0000-0002-2887-8451)
- Ripal Jariwala (ORCID: https://orcid.org/0000-0002-1377-908X)
- Jonathan Paul Singer (ORCID: https://orcid.org/0000-0003-0224-7472)
- Bo Yen (ORCID: https://orcid.org/0000-0003-4392-3027)
- Jasleen Kukreja (ORCID: https://orcid.org/0000-0003-2991-6680)
- Rachael Gordon
- Rebecca Florez (ORCID: https://orcid.org/0000-0002-4076-0085)
Institutions
- University of California, San Francisco (US)
Publication Details
- Journal
- Transplant Infectious Disease
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1111/tid.14402
- Citations
- 1
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.39